Importantly, ATA treatment caused decreased blood glucose, increased NR4A1 expression, PTPRD recovery, and insulin receptor activation, providing further insights into the effects of ATA on T2D and DNMT1 function. The gene discussed is DNMT1; the disease is type 2 diabetes mellitus.